NCT05754736View on ClinicalTrials.gov

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Ametinib combined with bevacizumab

Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w

Trial Locations (1)

271000

RECRUITING

The Second Affiliated Hospital of Shandong First Medical University, Tai’an

All Listed Sponsors
lead

The Second Affiliated Hospital of Shandong First Medical University

OTHER